Barry Salzman biography
Barry Salzman serves as Independent Director of the Company. Mr. Salzman is currently a Managing Director for Compass Partners LLC, a merchant banking and financial advisory firm that specializes in middle market companies and corporate restructuring. Mr. Salzman joined Compass Partners LLC in July 2007, the same time at which he became a Board Member and Principal owner of BP Gamma Medical Supply Company. Prior to July 2007, Mr. Salzman served as Board Chairman, President and Principal owner of Becker-Parkin Dental Supply Company. After 20 years at Becker-Parkin, Mr. Salzman sold the company to Henry Schein Inc. (NASDAQ: HSIC). Five months after selling Becker-Parkin, Mr. Salzman served as President of Surgery Works, LLC, formed by Compass Partners LLC to provide financial management services for Ambulatory Surgery Centers until the centers sold a controlling interest to Amsurg (NASDAQ: AMSG). Mr. Salzman has maintained a Board seat at both Surgery Works, LLC centers and continues to work in a consulting and advisory role to Amsurg. In 2014, Mr. Salzman founded and became President of Practice Management Works LLC and also accepted a board seat at Vivex Corporation, a private research driven Biomedical Company. Mr. Salzman is a 1987 graduate of Brooklyn Law School and is a member in good standing of the New York Bar Association. Based on Mr. Salzman’s financial industry experience and in-depth understanding of our business, as well as his extensive management experience, the Board of Directors believes that Mr. Salzman has the appropriate set of skills to serve as a member of the Board.
What is the salary of Barry Salzman?
As the Independent Director of Checkpoint Therapeutics Inc, the total compensation of Barry Salzman at Checkpoint Therapeutics Inc is 100,002$. There are 6 executives at Checkpoint Therapeutics Inc getting paid more, with James Oliviero having the highest compensation of 2,308,250$.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
How old is Barry Salzman?
Barry Salzman is 58, he's been the Independent Director of Checkpoint Therapeutics Inc since 2016. There are 3 older and 6 younger executives at Checkpoint Therapeutics Inc. The oldest executive at Checkpoint Therapeutics Inc is Lindsay Rosenwald, 65, who is the Director.
What's Barry Salzman's mailing address?
Barry's mailing address filed with the SEC is 95 SAWYER ROAD, SUITE 110, , WALTHAM, MA, 02453.
Insiders trading at Checkpoint Therapeutics Inc
Over the last 8 years, insiders at Checkpoint Therapeutics Inc have traded over 1,535,168$ worth of Checkpoint Therapeutics Inc stock and bought 200,000 units worth 356,000$ . The most active insiders traders include Lindsay A Md Rosenwald、Michael S Weiss、James F Iii Oliviero. On average, Checkpoint Therapeutics Inc executives and independent directors trade stock every 94 days with the average trade being worth of 93,898$. The most recent stock trade was executed by James F Iii Oliviero on 26 June 2024, trading 24,610 units of CKPT stock currently worth 50,451$.
What does Checkpoint Therapeutics Inc do?
checkpoint therapeutics, inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. the company's product candidates include ck-101 that in phase i clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and cosibelimab, a programmed death ligand-1 (pd-l1), which is in phase i clinical trial in patients with selected recurrent or metastatic cancers. it also develops ck-103, a small molecule inhibitor of bet bromodomains; and ck-302, a human agonistic antibody for oncology indications. checkpoint therapeutics, inc. has collaboration agreements with tg therapeutics, inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. the company was founded in 2014 and is headquartered in new york, new york. checkpoint therapeutics, inc. is a subsidiary of fortr
What does Checkpoint Therapeutics Inc's logo look like?
Checkpoint Therapeutics Inc executives and stock owners
Checkpoint Therapeutics Inc executives and other stock owners filed with the SEC include:
-
James Oliviero,
President, Chief Executive Officer, Director -
James F. Oliviero III, C.F.A., CFA,
Pres, CEO & Director -
William Gray,
Vice President - Finance and Accounting, Principal Financial Officer, Corporate Secretary -
William Garrett Gray,
CFO, Corp. Sec. & Treasurer -
Neil Herskowitz,
Independent Director -
Michael Weiss,
Chairman of the Board -
Barry Salzman,
Independent Director -
Scott Boilen,
Independent Director -
Christian Bechon,
Independent Director -
Lindsay Rosenwald,
Director -
Biotech, Inc. Fortress,
10% owner -
Sharma Amit,
Director